Research monograph · cyclic heptapeptide alpha-msh analog (mc3r/mc4r agonist)
Melanocortin Arousal Studies
This monograph collects what the published literature reports about PT-141 — its mechanisms, the areas it is studied in, its molecular record and the sources behind them. Its route of action is central rather than vascular — it signals in the nervous system rather than acting on blood flow directly, which distinguishes it mechanistically from other compounds studied for similar endpoints.
For laboratory research use only — not for human or animal use
Mechanisms
Melanocortin Receptor Agonism
Bremelanotide is a cyclic heptapeptide analogue of alpha-MSH that binds several melanocortin receptors, with MC3R and MC4R the subtypes of interest. Cyclisation confers the metabolic stability the linear hormone lacks.
Central Nervous Signalling
Unlike vasoactive compounds studied for overlapping endpoints, activity is described as central rather than peripheral. Published work locates the relevant MC4R populations in hypothalamic nuclei rather than in vascular tissue.
Downstream Neurotransmission
Preclinical models describe melanocortin activation producing downstream changes in dopaminergic signaling in the medial preoptic area, which is the mechanism most often proposed to connect receptor binding to the observed behavioral endpoints.
Studied applications
Used as a pharmacological probe of MC3R and MC4R activity, where its non-selectivity is a study limitation rather than a feature.
Molinoff et al. 2003
Rodent and primate models have measured behavioral endpoints following central melanocortin activation.
Pfaus et al. 2004
Studied across subcutaneous and intranasal administration, with the intranasal route largely abandoned on pharmacokinetic grounds.
Diamond et al. 2004
Binding-affinity work characterizes its activity across the full melanocortin receptor family rather than at a single subtype.
Rosen et al. 2004
FAQ
PT-141, also called bremelanotide, is a cyclic peptide that binds the MC3 and MC4 melanocortin receptors. Its route of action is central rather than vascular — it signals in the nervous system rather than acting on blood flow directly, which distinguishes it mechanistically from other compounds studied for similar endpoints.
Store the sealed vial at -20°C, protected from light and moisture, and let it reach room temperature before opening so condensation does not form on cold powder. Keep reconstituted solution refrigerated and avoid repeated freeze-thaw cycles — solutions are far less stable than lyophilized powder.
No. PT-141 is supplied strictly for in-vitro laboratory research and development. It is not a drug, food, supplement or cosmetic, it has not been evaluated by the FDA, and it is not intended for human or animal consumption, ingestion, injection or any in-vivo use. Ordering confirms you are a qualified researcher or institution purchasing on that basis.
Cited sources
Independent published research indexed from PubMed — not Routine Peptides claims.
Before you order
Every production run is analyzed by an independent laboratory, and the certificate for your lot travels with the order — not a catalog-wide document, and not a summary written by us.
